Effect of alpha-lipoic acid in ß-thalassemia major patients.

Effect of alpha-lipoic acid on risk factors of cardiovascular disease in ß-thalassemia major patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131013014994N6

Enrollment

Registered

2020-06-21

Start date

2018-07-23

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta thalassaemia. Beta thalassaemia

Interventions

Intervention 1: Intervention group: Take 1 tablet of 600 mg Alpha-lipoic acid daily for 8 weeks. American Manufacturing Corporation: Support Nutrition. Intervention 2: Control group: Each day, 1 place

Eligibility

Sex/Gender

All

Age

15 Years to 35 Years

Inclusion criteria

Inclusion criteria: Age: 15 - 35 years old

Exclusion criteria

Exclusion criteria: History of hepatitis B and C Heart failure, renal failure Cancer Allergies Digestive problems disrupting drug intake Pregnancy Smoking Consumption of other than desphonac Adherence to a particular diet

Design outcomes

Primary

Measure	Time frame
Homocysteine (HCY). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.;Lipoprotein-associated phospholipase A2 (Lp-PLA2). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.;Trimethylamine N-oxide (TMAO). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.;Osteoprotegerin (OPG). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.	—

Measure

Time frame

Homocysteine (HCY). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.;Lipoprotein-associated phospholipase A2 (Lp-PLA2). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.;Trimethylamine N-oxide (TMAO). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.;Osteoprotegerin (OPG). Timepoint: The beginning of the study and the end of week 8, 11 and 19. Method of measurement: Eliza.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Abdollahzad

Kermanshah University of Medical Sciences

hadi_nut@yahoo.com+98 83 3826 2052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026